Urology: Recent Episodes
ReachMD
Guest: Riley Bove, MD, MMSc
Many patients with multiple sclerosis (MS) experience neurogenic bladder symptoms—ranging from urgency and incontinence to retention and infection risk—but these issues are often underprioritized in care. Based on recent research, remote, commercially available bladder monitoring tools can help address this unmet need and uncover day-to-day fluctuations in bladder function. To learn more about this research, tune in to hear from Dr. Riley Bove. Not only is Dr. Bove a practicing neurologist and clinician scientist in the UCSF Weill Institute for Neurosciences, but she also presented a session on this exact topic at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting.
Guest: Ihtisham Ahmad
Preclinical findings in animal models have shown that activating cannibinoid receptors can shrink prostate tumors in animal models. To explore whether these effects translate to human populations, a recent study examined a potential link between cannabis use and the development of prostate cancer. Hear from Ihtisham Ahmad, a fourth-year medical student at the University of Toronto, as he explains the methodology and findings from his research, which he presented at the American Urological Association 2025 Annual Meeting.
Guest: Mutahar Ahmed, MD
Optimizing urinary diversion and continence techniques is essential for improving patient outcomes and quality of life following surgery. Join Dr. Mutahar Ahmed as he provides expert guidance on improving success in conduits and neobladders in the operating room and beyond. Dr. Ahmed is the Director of the Center for Bladder Cancer at Hackensack University Medical Center as well as a Professor of Urology and the Director of the Minimal Invasive Robotic Oncology and Urology Fellowship Program at Hackensack Meridian School of Medicine. He also presented on this topic at the 2025 American Urological Association Annual Meeting.
Guest: Wayne Kuang, MD
In an exciting time for diagnostics and therapeutics in urology, the discussions at the American Urological Association’s 2025 Annual Meeting are redefining the landscape of men’s health. Dr. Wayne Kuang, CEO of MD for Men in Albuquerque and Founder of the ManVsProstate campaign, highlights some of the most anticipated topics at this year’s conference, including prioritizing early intervention, preserving vitality, and expanding the focus beyond the prostate to protect the bladder.
Guest: Wayne Kuang, MD
Holistic health, fearless thinking, and proactive choices can be transformative in urological health. Dr. Wayne Kuang, CEO of MD for Men in Albuquerque and Founder of the ManVsProstate campaign, explores how we can create a future that works for everyone in the realm of urology.
Guest: Wayne Kuang, MD
The 2025 American Urology Association Annual Meeting promises to unite the global urology community across six continents around transformative education, game-changing trials, and a renewed focus on patient-centered care. Dr. Wayne Kuang, CEO of MD for Men in Albuquerque and Founder of the ManVsProstate campaign, dives into what makes this year’s conference truly exciting.
Host: Elizabeth R. Plimack, MD, MS, FASCO
Guest: Shilpa Gupta, MD
New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder cancer (mBC), with additional studies investigating its role in neoadjuvant and adjuvant treatments for muscle-invasive bladder cancer (MIBC). These newer immunotherapy treatments, however, can cause unique, sometimes life-threatening, adverse events (AEs).
This activity has been designed to review the latest treatment guidelines for mBC, explore emerging immunotherapy treatments in MIBC, and provide management strategies for common AEs seen with newer immunotherapy.
Guest: Bilal Chughtai, MD
Advancements in diagnostics and treatment have led to enhanced personalized care for patients with benign prostatic hyperplasia (BPH) and overactive bladder (OAB). Minimally invasive treatments have the potential to replace medication for BPH, while a greater focus on bladder health can help differentiate the two conditions and improve outcomes. Learn how these advances are shaping BPH and OAB management with Dr. Bilal Chughtai, Chief of Urology at Plainview Hospital and Associate Professor of Urology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.
Host: Ignacio Duran, MD
Host: Wenxin Xu, MD
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.
Host: Ignacio Duran, MD
Host: Wenxin Xu, MD
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.
Host: Ignacio Duran, MD
Host: Sandy Srinivas, MD
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.
Host: Ignacio Duran, MD
Host: Wenxin Xu, MD
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.
Host: Wenxin Xu, MD
Host: Sandy Srinivas, MD
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.
Host: Sandy Srinivas, MD
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.
Host: Wenxin Xu, MD
Host: Sandy Srinivas, MD
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.
Host: Ignacio Duran, MD
Host: Sandy Srinivas, MD
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.
Host: Ignacio Duran, MD
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.
Host: Wenxin Xu, MD
Host: Sandy Srinivas, MD
This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.
Host: Jason Hafron, MD
Guest: Carissa Chu. MD
Despite treatment advances in genitourinary cancers, most patients will develop relapsed disease. Thus, new treatment approaches are needed, as well as improved methods to identify patients who will derive the optimal benefit from established and emerging therapies. Real-world data provide crucial insight into practice patterns and response rates, ultimately guiding individualization of treatment selection. In this activity, expert faculty assess key findings from prostate and bladder cancer trials and explore the relevance of these data to clinical practice.
Host: Alicia K. Morgans, MD, MPH
Host: Kelvin A. Moses, MD, PhD, FACS
This program increases awareness of androgen deprivation therapy (ADT) as a mainstay of treating patients with metastatic hormone-sensitive prostate cancer (mHSPC) and leads to new opportunities to improve patient care. Recent developments create a need for a greater understanding of practice-changing clinical trial data and guideline recommendations to treat patients with mHSPC.
This program provides information on the most effective implementation of androgen receptor inhibitors (ARIs) to change the disease trajectory for mHSPC. In addition, this education addresses both the challenges of and the need for an interdisciplinary care model that includes oncology pharmacists and nurses who provide patient support and education. Effective interdisciplinary care improves adherence management of adverse effects (AEs) and helps reduce the barriers to access, care, and treatment that contribute to racial and ethnic disparities in prostate cancer treatment. Finally, a patient education solution completes the curriculum, providing clinician-developed videos tethered to and accessible via the HCP education to answer questions frequently faced by patients with prostate cancer.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Alicia K. Morgans, MD, MPH
This program increases awareness of androgen deprivation therapy (ADT) as a mainstay of treating patients with metastatic hormone-sensitive prostate cancer (mHSPC) and leads to new opportunities to improve patient care. Recent developments create a need for a greater understanding of practice-changing clinical trial data and guideline recommendations to treat patients with mHSPC.
This program provides information on the most effective implementation of androgen receptor inhibitors (ARIs) to change the disease trajectory for mHSPC. In addition, this education addresses both the challenges of and the need for an interdisciplinary care model that includes oncology pharmacists and nurses who provide patient support and education. Effective interdisciplinary care improves adherence management of adverse effects (AEs) and helps reduce the barriers to access, care, and treatment that contribute to racial and ethnic disparities in prostate cancer treatment. Finally, a patient education solution completes the curriculum, providing clinician-developed videos tethered to and accessible via the HCP education to answer questions frequently faced by patients with prostate cancer.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Kelvin A. Moses, MD, PhD, FACS
This program increases awareness of androgen deprivation therapy (ADT) as a mainstay of treating patients with metastatic hormone-sensitive prostate cancer (mHSPC) and leads to new opportunities to improve patient care. Recent developments create a need for a greater understanding of practice-changing clinical trial data and guideline recommendations to treat patients with mHSPC.
This program provides information on the most effective implementation of androgen receptor inhibitors (ARIs) to change the disease trajectory for mHSPC. In addition, this education addresses both the challenges of and the need for an interdisciplinary care model that includes oncology pharmacists and nurses who provide patient support and education. Effective interdisciplinary care improves adherence management of adverse effects (AEs) and helps reduce the barriers to access, care, and treatment that contribute to racial and ethnic disparities in prostate cancer treatment. Finally, a patient education solution completes the curriculum, providing clinician-developed videos tethered to and accessible via the HCP education to answer questions frequently faced by patients with prostate cancer.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Alicia K. Morgans, MD, MPH
Host: Kelvin A. Moses, MD, PhD, FACS
This program increases awareness of androgen deprivation therapy (ADT) as a mainstay of treating patients with metastatic hormone-sensitive prostate cancer (mHSPC) and leads to new opportunities to improve patient care. Recent developments create a need for a greater understanding of practice-changing clinical trial data and guideline recommendations to treat patients with mHSPC.
This program provides information on the most effective implementation of androgen receptor inhibitors (ARIs) to change the disease trajectory for mHSPC. In addition, this education addresses both the challenges of and the need for an interdisciplinary care model that includes oncology pharmacists and nurses who provide patient support and education. Effective interdisciplinary care improves adherence management of adverse effects (AEs) and helps reduce the barriers to access, care, and treatment that contribute to racial and ethnic disparities in prostate cancer treatment. Finally, a patient education solution completes the curriculum, providing clinician-developed videos tethered to and accessible via the HCP education to answer questions frequently faced by patients with prostate cancer.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Lisa Holle, PharmD, BCOP, FHOPA, FISOPP
This program increases awareness of androgen deprivation therapy (ADT) as a mainstay of treating patients with metastatic hormone-sensitive prostate cancer (mHSPC) and leads to new opportunities to improve patient care. Recent developments create a need for a greater understanding of practice-changing clinical trial data and guideline recommendations to treat patients with mHSPC.
This program provides information on the most effective implementation of androgen receptor inhibitors (ARIs) to change the disease trajectory for mHSPC. In addition, this education addresses both the challenges of and the need for an interdisciplinary care model that includes oncology pharmacists and nurses who provide patient support and education. Effective interdisciplinary care improves adherence management of adverse effects (AEs) and helps reduce the barriers to access, care, and treatment that contribute to racial and ethnic disparities in prostate cancer treatment. Finally, a patient education solution completes the curriculum, providing clinician-developed videos tethered to and accessible via the HCP education to answer questions frequently faced by patients with prostate cancer.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Stacy Walker, NP
This program increases awareness of androgen deprivation therapy (ADT) as a mainstay of treating patients with metastatic hormone-sensitive prostate cancer (mHSPC) and leads to new opportunities to improve patient care. Recent developments create a need for a greater understanding of practice-changing clinical trial data and guideline recommendations to treat patients with mHSPC.
This program provides information on the most effective implementation of androgen receptor inhibitors (ARIs) to change the disease trajectory for mHSPC. In addition, this education addresses both the challenges of and the need for an interdisciplinary care model that includes oncology pharmacists and nurses who provide patient support and education. Effective interdisciplinary care improves adherence management of adverse effects (AEs) and helps reduce the barriers to access, care, and treatment that contribute to racial and ethnic disparities in prostate cancer treatment. Finally, a patient education solution completes the curriculum, providing clinician-developed videos tethered to and accessible via the HCP education to answer questions frequently faced by patients with prostate cancer.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Kelvin A. Moses, MD, PhD, FACS
Host: Alicia K. Morgans, MD, MPH
This program increases awareness of androgen deprivation therapy (ADT) as a mainstay of treating patients with metastatic hormone-sensitive prostate cancer (mHSPC) and leads to new opportunities to improve patient care. Recent developments create a need for a greater understanding of practice-changing clinical trial data and guideline recommendations to treat patients with mHSPC.
This program provides information on the most effective implementation of androgen receptor inhibitors (ARIs) to change the disease trajectory for mHSPC. In addition, this education addresses both the challenges of and the need for an interdisciplinary care model that includes oncology pharmacists and nurses who provide patient support and education. Effective interdisciplinary care improves adherence management of adverse effects (AEs) and helps reduce the barriers to access, care, and treatment that contribute to racial and ethnic disparities in prostate cancer treatment. Finally, a patient education solution completes the curriculum, providing clinician-developed videos tethered to and accessible via the HCP education to answer questions frequently faced by patients with prostate cancer.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Alicia K. Morgans, MD, MPH
Host: Kelvin A. Moses, MD, PhD, FACS
This program increases awareness of androgen deprivation therapy (ADT) as a mainstay of treating patients with metastatic hormone-sensitive prostate cancer (mHSPC) and leads to new opportunities to improve patient care. Recent developments create a need for a greater understanding of practice-changing clinical trial data and guideline recommendations to treat patients with mHSPC.
This program provides information on the most effective implementation of androgen receptor inhibitors (ARIs) to change the disease trajectory for mHSPC. In addition, this education addresses both the challenges of and the need for an interdisciplinary care model that includes oncology pharmacists and nurses who provide patient support and education. Effective interdisciplinary care improves adherence management of adverse effects (AEs) and helps reduce the barriers to access, care, and treatment that contribute to racial and ethnic disparities in prostate cancer treatment. Finally, a patient education solution completes the curriculum, providing clinician-developed videos tethered to and accessible via the HCP education to answer questions frequently faced by patients with prostate cancer.
Video education created for patients is available for this topic. Visit www.mymededge.com to “prescribe” education that helps patients and caregivers learn more about this condition.
Host: Neeraj Agarwal, MD
Patients with high-risk, localized prostate cancer have an increased risk of developing metastases and experiencing prostate cancer-specific death compared to those with low- and intermediate-risk disease. The results of the STAMPEDE trial changed the standard of care for these patients, improving survival endpoints by intensifying androgen deprivation therapy (ADT) with the addition of abiraterone. Given the STAMPEDE data and the benefit of other second-generation androgen receptor inhibitors (ARIs) in later lines of therapy, researchers are evaluating the impact of utilizing ARIs earlier in the continuum of prostate cancer care. Despite growing consensus among experts that ADT alone is not enough for most high-risk patients with localized disease, treatment intensification remains underutilized. Our goal is to educate oncologists, urologists, radiologists, and other treatment team members on the duration of treatment, safety, and efficacy profiles of approved treatments as well as to provide additional insights on their potential for application in earlier settings.
Host: Rana McKay, MD
Patients with high-risk, localized prostate cancer have an increased risk of developing metastases and experiencing prostate cancer-specific death compared to those with low- and intermediate-risk disease. The results of the STAMPEDE trial changed the standard of care for these patients, improving survival endpoints by intensifying androgen deprivation therapy (ADT) with the addition of abiraterone. Given the STAMPEDE data and the benefit of other second-generation androgen receptor inhibitors (ARIs) in later lines of therapy, researchers are evaluating the impact of utilizing ARIs earlier in the continuum of prostate cancer care. Despite growing consensus among experts that ADT alone is not enough for most high-risk patients with localized disease, treatment intensification remains underutilized. Our goal is to educate oncologists, urologists, radiologists, and other treatment team members on the duration of treatment, safety, and efficacy profiles of approved treatments as well as to provide additional insights on their potential for application in earlier settings.
Host: Neeraj Agarwal, MD
Patients with high-risk, localized prostate cancer have an increased risk of developing metastases and experiencing prostate cancer-specific death compared to those with low- and intermediate-risk disease. The results of the STAMPEDE trial changed the standard of care for these patients, improving survival endpoints by intensifying androgen deprivation therapy (ADT) with the addition of abiraterone. Given the STAMPEDE data and the benefit of other second-generation androgen receptor inhibitors (ARIs) in later lines of therapy, researchers are evaluating the impact of utilizing ARIs earlier in the continuum of prostate cancer care. Despite growing consensus among experts that ADT alone is not enough for most high-risk patients with localized disease, treatment intensification remains underutilized. Our goal is to educate oncologists, urologists, radiologists, and other treatment team members on the duration of treatment, safety, and efficacy profiles of approved treatments as well as to provide additional insights on their potential for application in earlier settings.
Host: Rana McKay, MD
Patients with high-risk, localized prostate cancer have an increased risk of developing metastases and experiencing prostate cancer-specific death compared to those with low- and intermediate-risk disease. The results of the STAMPEDE trial changed the standard of care for these patients, improving survival endpoints by intensifying androgen deprivation therapy (ADT) with the addition of abiraterone. Given the STAMPEDE data and the benefit of other second-generation androgen receptor inhibitors (ARIs) in later lines of therapy, researchers are evaluating the impact of utilizing ARIs earlier in the continuum of prostate cancer care. Despite growing consensus among experts that ADT alone is not enough for most high-risk patients with localized disease, treatment intensification remains underutilized. Our goal is to educate oncologists, urologists, radiologists, and other treatment team members on the duration of treatment, safety, and efficacy profiles of approved treatments as well as to provide additional insights on their potential for application in earlier settings.
Host: Rana McKay, MD
Host: Neeraj Agarwal, MD
Patients with high-risk, localized prostate cancer have an increased risk of developing metastases and experiencing prostate cancer-specific death compared to those with low- and intermediate-risk disease. The results of the STAMPEDE trial changed the standard of care for these patients, improving survival endpoints by intensifying androgen deprivation therapy (ADT) with the addition of abiraterone. Given the STAMPEDE data and the benefit of other second-generation androgen receptor inhibitors (ARIs) in later lines of therapy, researchers are evaluating the impact of utilizing ARIs earlier in the continuum of prostate cancer care. Despite growing consensus among experts that ADT alone is not enough for most high-risk patients with localized disease, treatment intensification remains underutilized. Our goal is to educate oncologists, urologists, radiologists, and other treatment team members on the duration of treatment, safety, and efficacy profiles of approved treatments as well as to provide additional insights on their potential for application in earlier settings.
Host: Rana McKay, MD
Host: Neeraj Agarwal, MD
Patients with high-risk, localized prostate cancer have an increased risk of developing metastases and experiencing prostate cancer-specific death compared to those with low- and intermediate-risk disease. The results of the STAMPEDE trial changed the standard of care for these patients, improving survival endpoints by intensifying androgen deprivation therapy (ADT) with the addition of abiraterone. Given the STAMPEDE data and the benefit of other second-generation androgen receptor inhibitors (ARIs) in later lines of therapy, researchers are evaluating the impact of utilizing ARIs earlier in the continuum of prostate cancer care. Despite growing consensus among experts that ADT alone is not enough for most high-risk patients with localized disease, treatment intensification remains underutilized. Our goal is to educate oncologists, urologists, radiologists, and other treatment team members on the duration of treatment, safety, and efficacy profiles of approved treatments as well as to provide additional insights on their potential for application in earlier settings.
Host: Rana McKay, MD
Patients with high-risk, localized prostate cancer have an increased risk of developing metastases and experiencing prostate cancer-specific death compared to those with low- and intermediate-risk disease. The results of the STAMPEDE trial changed the standard of care for these patients, improving survival endpoints by intensifying androgen deprivation therapy (ADT) with the addition of abiraterone. Given the STAMPEDE data and the benefit of other second-generation androgen receptor inhibitors (ARIs) in later lines of therapy, researchers are evaluating the impact of utilizing ARIs earlier in the continuum of prostate cancer care. Despite growing consensus among experts that ADT alone is not enough for most high-risk patients with localized disease, treatment intensification remains underutilized. Our goal is to educate oncologists, urologists, radiologists, and other treatment team members on the duration of treatment, safety, and efficacy profiles of approved treatments as well as to provide additional insights on their potential for application in earlier settings.
Host: Petros Grivas, MD, PhD
Guest: Thomas Powles, MD, PhD
Survival for patients with metastatic urothelial cancer has increased with the approval of immune therapy, antibody-drug conjugates, and targeted agents. In the maintenance setting, avelumab has become the global standard of care. Do you know how to evaluate and effectively implement immune therapy in the maintenance setting in your practice?
Host: Marshall Miller
Relieve yourself of any curiosity surrounding the history of uroscopy with our whiz-bang host Marshall Miller.
Host: Mamta Parikh, MD, MS
Guest: Daniel P. Petrylak, MD
Do you know how to best utilize immunotherapy and antibody-drug conjugates to improve treatment outcomes in your patients with metastatic urothelial cancer? Listen in as Drs. Mamta Parikh and Daniel Petrylak break down the data surrounding these therapies so you can improve the care you provide.
Host: Eric Jonasch, MD
Guest: Brad McGregor, MD
Do you know how to best utilize immunotherapy to improve treatment outcomes in your patients with metastatic renal cell cancer? Listen as Drs. Eric Jonasch and Bradley McGregor discuss the data and guidelines surrounding selecting and sequencing immunotherapy for your patients.
Host: Ayse Tuba Kendi, MD
Guest: A. Oliver Sartor, MD
Prostate-specific membrane antigen (PSMA) is highly expressed on prostate cancer (PC) cells and can be detected in tumors using positron emission tomography imaging. Even though clinical features predict different stages of PC progression, the application of imaging to guide treatment is still evolving but gaining substantial evidence for the targeting of PSMA. With clinical research shifting paradigms for the treatment of metastatic castration-resistant prostate cancer (mCRPC), novel treatment options require adoption and effective application into clinical practice. PSMA has become an appealing target for diagnostic agents for imaging and therapeutic agents to treat mCRPC. Radionuclide emitters are being used for both cell surface expression of PSMA and the tumor microenvironment, and research has proven the therapeutic efficacy of PSMA-directed radioligand therapy (RLT).
In this educational activity, two experts will examine the role and rationale for PSMA targeted therapies and diagnostics—jointly known as theragnostics—as a revolutionary new approach to treating patients with advanced prostate cancer and will evaluate clinical trial data for PSMA-targeted RLT.
Host: Ayse Tuba Kendi, MD
Guest: A. Oliver Sartor, MD
Prostate cancer–specific antigen (PSMA) is highly expressed on prostate cancer (PC) cells and can be detected in tumors using positron emission tomography imaging. Even though clinical features predict different stages of PC progression, the application of imaging to guide treatment is still evolving but gaining substantial evidence for the targeting of PSMA. With clinical research shifting paradigms for the treatment of metastatic castration-resistant prostate cancer (mCRPC), novel treatment options require adoption and effective application into clinical practice. PSMA has become an appealing target for diagnostic agents for imaging and therapeutic agents to treat mCRPC. Radionuclide emitters are being used for both cell surface expression of PSMA and the tumor microenvironment, and research has proven the therapeutic efficacy of PSMA-directed radioligand therapy (RLT).
In this educational activity, two experts will examine the role and rationale for PSMA targeted therapies and diagnostics—jointly known as theragnostics—as a revolutionary new approach to treating patients with advanced prostate cancer and will evaluate clinical trial data for PSMA-targeted RLT.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Nick Kusnezov, MD
Can you balance locum tenens with a full-time career? To answer that question, Dr. Charles Turck is joined by board-certified orthopedic surgeon, Dr. Nicholas Kusnezov, to walk us through his journey from joining the military to locum tenens.
Host: Jennifer Caudle, DO
Guest: Roni Devlin, MD
As rates of burnout continue to rise in the healthcare community, how can help our female physicians combat it? Dr. Jennifer Caudle joins Infectious Disease Specialist, Dr. Roni Devlin, to discuss how we can prevent burnout for female physicians.
Host: Paul P. Doghramji, MD, FAAFP
Guest: Samantha Conroy, MD
Locum tenens can improve quality of care around the globe—especially in remote and underserved communities. To share how, Dr. Paul Doghramji joins Dr. Samantha Conroy, a family practice obstetrician to share her experiences working as a locum tenens obstetrician in underserved communities.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Trevor Cabrera, MD
What’s it like becoming a locum tenens physician right out of residency? Dr. Charles Turck joins Dr. Trevor Cabrera, a Board-Certified pediatrician who trained in Houston, Texas, to share his firsthand experience and offer advice for residents.
Host: Jennifer Caudle, DO
Guest: Maurice G. Sholas, MD, PhD
After years of serving the New Orleans community, one physician decided to pursue locum tenens work. Dr. Jennifer Caudle joins Dr. Maurice Sholas, a pediatric physical rehabilitation physician, to share his experiences with locum tenens and in New Orleans.
Host: John J. Russell, MD
Guest: Joseph E. Bavaria, MD
Featuring a wide range of disciplines and a new approach to comprehensive care, what do we need to know about the Aorta Center at Penn Medicine? Dr. John Russell is joined by Dr. Joseph E. Bavaria to dive into this aortic program and discuss a new approach to comprehensive care.
Host: Jacob Sands, MD
Guest: Yasmin Jayasinghe, FRANZCOG, PhD
Pediatric and adolescent oncofertility patients are cared for differently than adult patients. That’s why Dr. Yasmin Jayasinghe, Director of the Oncofertility Program at the Royal Children’s Hospital, is here to give us an overview of the available procedures for pediatric patients and the key considerations that go along with them.
Host: Jacob Sands, MD
Guest: Yasmin Jayasinghe, FRANZCOG, PhD
Cancer treatment can impact fertility outcomes for individuals throughout the U.S. as well as around the globe, which is why the emerging field of oncofertility is here to help male and female patients navigate their fertility options before and after their cancer treatments. So what can we learn from oncofertility services and efforts from other countries around the world? Joining Dr. Jacob Sands to share her global viewpoints on the field of oncofertility is Dr. Yasmin Jayasinghe, Director of the Oncofertility Program at the Royal Children’s Hospital.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Kathryn Gallagher, MS, RN, BSN
Guest: Kate Newcomb-DeSanto, MSN, RN, MSW
What does Penn Medicine’s newly-opened patient room facility have to offer? Dr. Charles Turck is joined by Penn Medicine Clinical Advisors Kathy Gallagher and Kate Newcomb-DeSanto to discuss the new pavilion and how it's revolutionizing patient care.
Host: Jonathan C. Routh, MD, MPH, FAAP
Guest: Benjamin M. Whittam, MD, MS, FAAP, FACS
This Expert Exchange webcast is designed to enhance clinicians’ awareness of advances in the pharmacotherapeutic armamentarium for treating NDO in the pediatric population.
View the Advances in the Treatment of Neurogenic Detrusor Overactivity Clinical Compendium here: https://cdn.reachmd.com/uploads/clinicalcompendium_ndo_v2_final.pdf
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Sandy Marks
Guest: Kim Horvath, JD
Guest: Kyle Thomson, JD
With telehealth services expanding during the COVID-19 pandemic, has our access to them changed? To better understand this, Dr. Charles Turck meets with Sandy Marks, Kim Horvath, and Kyle Thomson from the AMA to explore what’s been done to provide Medicare coverage during a public health emergency and what’s on the horizon for telehealth access.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Emily Carroll, JD, MSW
The No Surprises Act aims to protect consumers from surprise medical bills. But how exactly does it go about doing that, and what’s the current status of its implementation? Joining Dr. Charles Turck to share progress and challenges associated with the No Surprises Act is Ms. Emily Carroll, a senior legislative attorney for the American Medical Association's Advocacy Resource Center.
Host: Daniel P. Petrylak, MD
Guest: Arlene O. Siefker-Radtke, MD
It's critical that we select and sequence appropriate therapeutics to provide our patients with the best possible outcomes. Dr. Petrylak and Dr. Siefker-Radtke provide a rundown of multiple disease factors to consider, evolving clinical trial data, and the various therapeutic options available in the second and subsequent lines of therapy for patients with locally advanced or metastatic urothelial carcinoma. With so many new treatment options now available and a cure becoming a real possibility, we invite you to tune in to find out if your treatment strategies are on target.
Host: Jennifer Caudle, DO
Guest: Sarah Ali, MD
From working in a big city to taking on an assignment in a small mountain village, Dr. Sarah Ali from the Ventura County Medical Center joins Dr. Jennifer Caudle to talk about her adventures abroad with locum tenens and share key lessons she learned along the way.
Host: Jacob Sands, MD
Guest: Suneeta Senapati, MD, MSCE
Guest: Mindy Christianson, MD
Patients undergoing treatments such as chemotherapy may be at significant risk of impairment or inability to have children later in life. This risk impacts both men and women equally, but fortunately, the field of oncofertility can help guide patients as they navigate their fertility options prior to cancer treatment. Here to share their insights on this emerging field with Dr. Jacob Sands are Dr. Mindy Christianson and Dr. Suneeta Senapati.
Host: Lauren Ritterhouse, MD ,PhD
Guest: Pasi Antero Jänne, MD, PhD
Guest: Kanwal Raghav, MD
HER3 is the new marker on the block, but is it diagnostic, predictive, or prognostic? Hear from the experts, Drs. Lauren Ritterhouse, Pasi Jänne, and Kanwal Raghav, as they explore the role of HER3 in oncogenesis and resistance to EGFR TKIs. Find out how we can now target HER3 signaling in metastatic solid tumors through the use of emerging HER3-targeted therapies along with novel and exciting antibody-drug conjugate studies and strategies.
*Since the recording of this activity, clinical trial NCT04479436, patritumab deruxtecan in colorectal cancer, has been terminated early. To learn more about this trial, search for NCT04479436 on ClinicalTrials.gov.
Host: Jennifer Caudle, DO
Guest: Erik Munson, Ph.D
Mycoplasma genitalium (M. gen) is an STI that shares similar health consequences to chlamydia and gonorrhea. Further complicating this health threat is the fact that there’s been little guidance on how to manage this new pathogen until recently when the 2021 STI Treatment Guidelines were released. Joining Dr. Jennifer Caudle to talk about M. gen and why the guidelines recommend the use of nucleic acid amplification tests for the diagnosis of this pathogen is Dr. Erik Munson, an Assistant Professor of Clinical Laboratory Science at Marquette University.
Host: Johann de Bono, MD, PhD
Guest: Alicia K. Morgans, MD, MPH
Prostate cancer is the second most common cancer in incidence and the fifth most frequent cause of cancer-related mortality in men worldwide. With the broader availability of PSA screenings, the incidence of disease is only rising.
This lively discussion focused on prostate cancer is designed to help you keep pace in GU cancers. You will enhance your knowledge and skills related to targeted therapy in patients with metastatic castrate-resistant prostate cancer, discover relevant biomarkers in prostate cancer, follow a patient case example, and hear about the latest clinical trial data presented at ASCO and ESMO 2021.
The prostate cancer landscape is rapidly evolving, so tune in to find out what changes you can make in your daily practice today.
Host: Paul P. Doghramji, MD, FAAFP
Guest: Mojgan Saber, MD
Can Locum Tenens be an option for healthcare professionals just completing their residency? Dr. Paul Doghramji is joined by Dr. Mojgan Saber to share her own experience as well as tips and tricks for residents looking at Locum Tenens right after residency.
Host: Charles P. Vega, MD
Guest: Sateria Venable
Regional healthcare disparities are biases that are based on where people live. Are your patients’ treatment options being impacted and limited by their geographical location? Join us as our two experts discuss how to support broader policy issues and highlight the importance of diagnostic algorithms that have been developed with diverse input. These steps may be of value in your clinical practice to ensure all patients have equal access to care regardless of their epidemiologic, socioeconomic, or insurance circumstances.
Host: Charles P. Vega, MD
Guest: Lionel Phillips, MBA
Learn why diversity in clinical trials is so important to community health. Two experts discuss the key role that trusted messengers play in enrollment, why it is critical to break the cycle of medical mistrust, and the downstream effect of a lack of diversity in clinical trials.
Host: Charles P. Vega, MD
Guest: Candice Taylor Lucas, MD, MPH, FAAP
What is cultural humility, and how can it be incorporated into clinical practice? How does your patient's culture impact their health behaviors, and why does your culture matter?
Listen in as two leading experts navigate concerns surrounding cultural humility and emphasize the importance of empathy, awareness, and advocacy. Discover ways to integrate small but important changes into your clinical practice to help bridge communication gaps and enable your patients to thrive.
Host: Charles P. Vega, MD
Guest: Robert O. Roswell, MD, FACC, FACP
Diversifying our physician workforce so that it is more racially, ethnically, and geographically balanced can ultimately have a positive impact on community health. Join us as two experts discuss how pipeline programs reaching children as early as elementary school can help ensure workplace diversity. Also find out how clinicians can be advocates for their patients by helping to disentangle them from structural inequities and working towards policy changes. There’s a lot than can be done to provide more balanced care, but we need to look beyond simple fixes to the root causes of the issues. So find your bandwidth – that’s what you can do today – and discover why it’s so important to move upstream to solve the problems manifesting downstream.
Host: Arjun V. Balar, MD
Guest: Daniel P. Petrylak, MD
Bladder cancer is the sixth most common malignancy in the United States. Many of these patients present with multiple comorbidities which creates a considerable challenge for clinicians when determining an appropriate treatment plan. Until recently, platinum-based chemotherapy was the only viable systemic therapy option for patients with locally advanced or metastatic urothelial cancer (mUC); however, the majority of these patients eventually relapse and need subsequent lines of therapy. Patients are then left with limited treatment options and often poor outcomes, contributing to a largely unmet need that prompted investigation into new and promising therapeutic options.
This chapterized activity is designed to update clinicians who treat locally advanced or metastatic urothelial cancer on new clinical trials and the treatment guidelines that align with the identified unmet need of subsequent treatment options for this patient population. Drs. Arjun Balar and Daniel Petrylak focus on enhancing the knowledge and skills of clinicians through case-based content to demonstrate individualized patient treatment plans and enable participants to further incorporate changes into their clinical practice. Join us to find out why the future is bright for our patients with mUC.
Host: Robert Mocharnuk, MD
Guest: Johann de Bono, MD, PhD
Guest: Neeraj Agarwal, MD
During recent years, advances in the understanding of the underlying genetic events and biology in prostate cancer development, including the DDR and MMR pathway alterations, have yielded new avenues for clinical exploration. Prostate cancers with deleterious aberrations in DNA damage repair (DDR) genes, including homologous recombination repair, such as mutations in BRCA1/2 and ATM, are associated with response to poly (adenosine diphosphate–ribose) polymerase (PARP) inhibition.
PARP inhibitors are now gaining FDA approvals for the treatment of patients with mCRPC, and ongoing clinical trials are evaluating these PARP inhibitors as monotherapy or in combination with other treatments such as androgen pathway inhibitors. The National Comprehensive Cancer Network (NCCN®) is now recommending germline testing and molecular biomarker analysis, including tumor testing for HRR mutations, and to consider tumor testing for MSI or dMMR for metastatic disease. PARP inhibitors for the treatment of mCRPC in patients harboring germline and somatic BRCA/ATM mutations, and in combination with androgen pathway inhibition, are poised to propel the management of mCRPC toward a more personalized approach.
In this activity, expert faculty will review, discuss, and provide their expert insights on recent and emerging practice-changing advancements with PARP inhibitors for the treatment of mCRPC, with a …
Host: Matt Birnholz, MD
Guest: Christopher P. Evans, M.D., F.A.C.S.
Guest: Maha Hussain, MD, FACP, FASCO
Prostate cancer is one of the most common cancers in men in the United States. In a program sponsored by Astellas and Pfizer, Drs. Maha Hussain and Christopher Evans discuss the history and how care is evolving for men with metastatic prostate cancer and non-metastatic castration-resistant prostate cancer.
This program is intended for United States health care professionals only. Drs. Hussain and Evans have recevied compensation from Astellas and Pfizer for their time.
074-0391-PM
Host: Paul Doghramji, MD
Guest: Alexander W. Pastuszak, MD, PhD
Put your knowledge of male infertility diagnosis and treatment strategies to the test with Dr. Alexander Pastuszak, an Assistant Professor at the University of Utah School of Medicine, as he breaks down its common causes and how we can improve care for our male patients.
Host: Paul Doghramji, MD
Guest: Alexander W. Pastuszak, MD, PhD
Even though hypogonadism is common among men, there are still some misconceptions surrounding it. So to learn more about how we can better diagnose and treat hypogonadism in our male patients, Dr. Paul Doghramji sits down with Dr. Alexander Pastuszak, an Assistant Professor at the University of Utah School of Medicine.
Host: Paul P. Doghramji, MD, FAAFP
Guest: Alexander W. Pastuszak, MD, PhD
While Peyronie’s disease isn’t the most comfortable topic to talk about with your male patients, avoiding it only fuels its under-recognition. So joining Dr. Paul Doghramji to discuss conversation-starter strategies—and what to do once you have that conversation and reach a diagnosis—is Dr. Alexander Pastuszak, a urologist at the University of Utah School of Medicine in Salt Lake City who specializes in the treatment of male infertility and sexual dysfunction.
Host: Alan S. Brown, MD, FACC, FAHA, FNLA
Live from the Clinical Lipid Update of the National Lipid Association in Amelia Island, FL, host Dr. Alan Brown welcomes Dr. Robert Kloner, Vice President of Translation at Huntington Medical Research Institutes and Professor of Medicine in the Cardiovascular Division of Keck School of Medicine at the University of Southern California.
Dr. Kloner discusses the cardiovascular risk factors associated with erectile dysfunction, safety and efficacy of erectile disfunction drugs, and benefits vs risks of supplementing with testosterone.
Host: Brian P. McDonough, MD, FAAFP
Guest: Charles N. Walker, MD
Dr. Charles Walker, Assistant Professor of Surgery in the Department of Urology at Yale University School of Medicine, shares clinical insights about penile prostheses, such as inflatable versus malleable devices, used as surgical gold standards to treat erectile dysfunction.
Host: Shira Johnson, MD
Guest: Charles N. Walker, MD
Dr. Shira Johnson speaks with Dr. Charles Walker, Assistant Professor of Surgery in the Department of Urology at Yale University School of Medicine. The two focus on erectile dysfunction as a common complication for patients dealing with diabetes and heart disease, and ways that clinicians can help patients manage this problem through lifestyle modifications. Dr. Walker also introduces emerging pathophysiological understandings of ED as a potential predictor of diabetes.
Host: Brian P. McDonough, MD, FAAFP
Kidney stones are on the rise, particularly among adolescents, females, and African-Americans in the U.S. This marks a striking change from the historic pattern in which middle-aged white men were at highest risk for the painful condition. While the overall increase in kidney stones in children and adolescents has been known, a recent study published in the Clinical Journal of the American Society of Nephrology provided greater clarity on the specific groups of patients at greatest risk by analyzing age, race and sex characteristics among children and adults in South Carolina over a 16-year period, from 1997 to 2012.
Lead author Dr. Gregory Tasian, Assistant Professor of Urology at the University of Pennsylvania Perelman School of Medicine and an attending pediatric urologist at The Children's Hospital of Philadelphia, joins Dr. Brian McDonough to discuss this startling trend, the factors that may be driving it, and appropriate preventive and treatment strategies for kidney stones.
Host: Prathima Setty, MD
Disorders of sex development (DSDs) occur more frequently than most people realize, and yet there are numerous misconceptions persisting in the clinical arena as to how these disorders are best approached. For example, whereas older prevailing sentiments on presentations of ambiguous genitalia called for immediate sex assignments at birth followed by surgical alignments of those decisions, more modern philosophies advocate for direct patient involvement in these decisions a little later in life.
Joining Dr. Prathima Setty to focus on this important topic is Dr. Earl Cheng, Professor of Urology, Division Head of Urology and Co-Head of Reconstructive Pediatric Urology at Northwestern University Feinberg School of Medicine. Dr. Cheng directs the Gender and Sex Development Program at Ann & Robert H. Lurie Children's Hospital of Chicago.
Host: Michael Krychman, MD
Bladder leakage is one of many health-related issues that our female patients deal with. There are newly available treatment options, including non-surgical options, to help remedy the problem. Host Dr. Michael Krychman welcomes Dr. Holly Thacker to decipher the pros and cons of the various options available. Dr. Holly L. Thacker, nationally known for her leadership in women’s health, is the founder of the Cleveland Clinic Women’s Health Fellowship and is currently Professor and Director of the Center for Specialized Women’s Health at Cleveland Clinic and Lerner College of Medicine at Case Western Reserve University. She is also author of two books: Women’s Health: Your Body, Your Hormones, Your Choices and Cleveland Clinic Guide to Menopause.
Host: Lee Freedman, MD
Given the multitude of concerns a male patient with cancer must deal with, sexual dysfunction and infertility are two such concerns that often gets bypassed by clinicians addressing more "priority" issues. What kinds of challenges do these patients deal with, and how can physicians better assess and manage them? Joining Dr. Freedman to discuss sexual health and fertility in male cancer survivors is Dr. Puneet Masson, Director of the Male Infertility Program and Assistant Professor of Urology at Penn Medicine.
Host: Lee Freedman, MD
Guest: Thomas Guzzo, MD, MPH
With 70,000 new cases each year in the US, bladder cancer is more common than many Americans may realize. As many as half of cases are caused by smoking, and many others are caused by environmental or occupational exposure. In determining appropriate treatment, staging and diagnosis are critical. Dr. Thomas Guzzo discusses the various treatment options with host Lee Freedman, with the overall goal to preserve quality of life. As a surgeon trained in a wide variety of surgical options, Dr. Guzzo discusses the advantages of each. He also discusses urinary diversions, including the neobladder.
Host: Matt Birnholz, MD
Host: Michael Greenberg, MD
Guest: Anthony Atala, MD
This week's guest is Dr. Anthony Atala, who oversees the world's largest lab devoted to bioengineering body parts, from inkjet-printed hearts to tiny livers, at Wake Forest University in Winston-Salem, North Carolina. He gives us an update from the cutting edge of medicine. Also, we get to the bottom line on how to protect your earnings in the coming tax year. And we talk with Dr. Marya Zilberberg about her recent article on The Healthcare Blog on medical testing and an approach toward a "less is more" philosophy of patient care.
Guest: Helen Carcio, NP
Host: Mimi Secor, DNP, FNP-BC, FAANP
More than 33 million people in the United States suffer from overactive bladder problems. Bladder health programs are being established in existing and new clinics to treat this issue that is rapidly growing, especially among the elderly. NP Helen Carcio began a certification program on the internet that teaches medical entrepreneurs how to establish these clinics. She joins host Mimi Secor to discuss start-up costs, the treatment process and the role of the NP and PA in this groundbreaking new expertise.
Host: Maureen Whelihan, MD
Guest: Stanley Althof, PhD
Most men who deal with erectile dysfunction (ED) suffer in silence because they don't know how to approach the subject with their doctor. How can you make it easier for your patients to talk about this sometimes embarrassing issue? Dr. Stanley Althof, professor emeritus at Case Western Reserve University School of Medicine, joins host Dr. Maureen Whelihan as they look at the biological and psychological causes of ED as well as the impact it can have on the health of couples.
Host: Eric Tangalos, MD
Guest: Manjula Kurella Tamura, MD, MPH
How do the processes leading to kidney failure differ for various patient populations? What special considerations should physicians keep in mind when caring for patients in long-term care facilities undergoing dialysis? Dr. Manjula Kurella Tamura, nephrologist and assistant professor of medicine at Stanford University School of Medicine, reviews findings from a study regarding functionality for patients undergoing dialysis. Dr. Kurella Tamura points out that although dialysis may increase longevity, it may not improve quality of life. What is recommended for optimal care of patients with kidney failure? Hosted by Dr. Eric Tangalos.
In two large randomized trials, researchers examined the effect of annual prostate-specific antigen (PSA) screening on the rate of death from prostate cancer and found that it was small and was offset by false positive diagnoses. Since screening may have benefits in catching cancers early but may also carry risks including that of unnecessary treatment, professional societies have split on the question of whether to recommend regular PSA screening. In a roundtable discussion moderated by Dr. Thomas Lee, oncologist Dr. Philip Kantoff and primary care physician Dr. Mary McNaughton-Collins debate the clinical implications of the new findings and the best way to advise patients about undergoing PSA testing.
Guest: David Ward, MD
Host: Steven Edelman, MD
Diabetes is the most common cause of kidney failure. However, most people with diabetes can avoid end-stage kidney disease and minimize their risk of kidney failure with intensive management of diabetes. Join host Dr. Steven Edelman and his guest, nephrologist and professor of medicine at the University of California San Diego, Dr. David Ward as they discuss diagnosis, symptoms, prevention and treatment of diabetic kidney disease.
Guest: R. Jeffrey Karnes, MD
Host: Lee Freedman, MD
Guest: Jennifer St. Sauver, PhD
Three recent observational studies from the Olmsted County Study of Urinary Health Status among Men, which is a cohort study of male residents of Olmsted County, Minnesota, have shown that statins may have a protective effect on prostate health. How might statins reduce the risk of prostate cancer, prostate enlargement and erectile dysfunction? Tune in to hear two of the study authors discuss this exciting new research: Dr. Jeffrey Karnes, assistant professor in urologic oncology, and Dr. Jennifer St. Sauver, assistant professor of epidemiology, both from the Mayo Clinic in Rochester, Minnesota. Dr. Lee Freedman hosts.
Host: Maurice Pickard, MD
Guest: Abraham Morgentaler, MD
It is widely believed that testosterone therapy for men with low testosterone can lead to an increased risk of prostate cancer. Dr. Abraham Morgentaler, associate clinical professor of urology at Harvard Medical School and author of the book Testosterone for Life, recalls the fascinating story of how this idea of high testosterone levels increasing the risk of prostate cancer originated, and suggests that in fact, the opposite might be true. What evidence supports boosting testosterone levels in men with low levels of the hormone, and that this might not raise a man's risk of developing prostate cancer? Hosted by Dr. Maurice Pickard.
Host: Shira Johnson, MD
Guest: Stephen Schwartz, PhD
Approximately 8000 men are diagnosed every year with testicular cancer in the United States. A first-of-its-kind study looked at whether or not marijuana use increases the risk. Dr. Stephen Schwartz, one of the researchers on the study and professor of epidemiology at the University of Washington, discusses his findings with host Dr. Shira Johnson. The two discuss how the research was conducted, who took part, and what needs to be done in the future to find more definitive answers.
Guest: Gary D. Steinberg, MD
Host: Mark Nolan Hill, MD
Early diagnosis of bladder cancer is a significant step toward survival. Over the years, findings have suggested that women and African-Americans are particularly vulnerable to the disease, and often times, we are delayed in our diagnosis and subsequent treatment of these more highly susceptible populations. What are the most effective steps we can take to improve our recognition of bladder cancer earlier in its progression? Host Dr. Mark Nolan Hill welcomes Dr. Gary Steinberg, professor and vice chairman of urology, and director of urologic oncology at the University of Chicago Pritzker School of Medicine, to discuss the key issues relative to gender and race, as well as awareness among patients and primary care physicians toward prevention of a delayed diagnosis of bladder cancer.
Host: Lee Freedman, MD
Guest: David I. Lee, MD
Newer options for treating prostate cancer include cryosurgery and robotic prostatectomy. What does each of these methods involve and how can we determine the best treatment for our patients? Dr. David I. Lee, assistant professor of surgery at Penn Medicine, explores the advantages, risks, and outcomes. Dr. Lee Freedman hosts.
Guest: Judith Florendo
Host: Lauren Streicher, MD
Treatment of pelvic pain is often handled by a gynecologist. The most successful approach to treating pelvic pain and dyspareunia may be a team approach. Judith Florendo, the Midwest regional representative in the women's section of the American Physical Therapy Association, joins host Dr. Lauren Streicher to discuss how pelvic physical therapists determine treatment for the problem. It begins with a complete medical history, and may include ultrasound, biofeedback, internal exams of the pelvis and electrical stimulation. The two also look at the significant increase in quality of life following treatment and the length of treatment for women with pelvic pain.
Guest: James L. Gulley, MD, PhD, FACP
Host: Maurice Pickard, MD
Can a vaccination help prevent prostate cancer? Dr. James Gulley, director of the Clinical Trials Group of the Laboratory of Tumor Immunology and Biology at the National Institutes of Health discusses studies involving the use of cancer vaccines to modulate the immune response in cancer patients. These trials contrast classic "tumor response" with "patient response" that have shown increased survival post therapy.
Guest: Elizabeth Kavaler, MD
Host: Lisa Mazzullo, MD
One in 10 American women reports a medically confirmed urinary tract infection (UTI) every year. Combined with the rise of antibiotic resistance in the treatment of cystitis, this has prompted the American College of Obstetrics and Gynecology to amend their guidelines on traditional UTI therapy for women of reproductive age. Dr. Elizabeth Kavaler, urologist at Lenox Hill Hospital in New York City, joins host Dr. Lisa Mazzullo to examine these guidelines, and to share treatment advice for urogenital infections.
Guest: Joseph Harryhill, MD
Host: Lee Freedman, MD
Dr. Joseph Harryhill, assistant clinical professor of surgery at the University of Pennsylvania School of Medicine, outlines procedural considerations for men with benign prostatic hyperplasiawith host Dr. Lee Freedman. Dr. Harryhill provides a contrast between more traditional approaches and newer therapies, including the GreenLight laser. Should you be referring your patients for laser therapy? If so, what might be the expected outcome?
Guest: Jim Hu, MD, MPH
Host: Mark Nolan Hill, MD
We are still working to minimize the major risks of complications involved in minimally invasive prostatectomy. This becomes even more important as more patients undergo these procedures. How has the training and certification process impacted our success? What improvements can we expect in this minimally invasive technique to treat prostate cancer in the years to come? For answers to these questions and many more, host Dr. Mark Nolan Hill welcomes Dr. Jim Hu, assistant professor of surgery at Harvard Medical School, and director of minimally invasive urologic oncology at Brigham and Women's Hospital and the Dana Farber Cancer Institute in Boston.
Guest: Jim Hu, MD, MPH
Host: Mark Nolan Hill, MD
Research indicates that demand for minimally invasive prostatectomy is growing, from 12 percent to more than 30 percent of our candidate patients over a recent two-year span. But research also tells us that there are still drawbacks to a laparoscopic approach to prostate cancer. What are the immediate and enduring pitfalls to laparoscopy, and are these concerns outweighed by the perceived benefits? Dr. Jim Hu, assistant professor of surgery at Harvard Medical School, and director of minimally invasive urologic oncology at Brigham and Women's Hospital and the Dana Farber Cancer Institute in Boston, explains why some surgeons may stick with the open procedure, even as others move ahead with the laparoscopic approach. Dr. Mark Nolan Hill hosts.
Guest: Stewart Justman, PhD
Host: Maurice Pickard, MD
Professor Stewart Justman discusses his new book "Do No Harm" in which the results of finasteride trial that ended in 2003 are looked at again. By reducing the size of the gland, what previously had appeared to be causing increased aggressive cancers may now be called into question. We will have to decide whether a healthy man should take a treatment to prevent a disease he may never get and if he did might be better off in not going through treatment.
Guest: Stewart Justman, PhD
Host: Maurice Pickard, MD
Professor Stewart Justman discusses his new book "Do No Harm" in which the results of the Prostate Cancer Prevention Trial cause us to reflect on Hippocratic ethical principals of 300BCE in our present practice. Finasteride leaves us with an ambiguity of reducing the incidence of cancer but also associated with a higher rate of aggressive neoplasm. In chemoprevention is any risk too much to be expectable? Hosted by Maurie Pickard.
Guest: Ash Tewari, MD
Host: Bruce Bloom, DDS, JD
Does robotic surgery for radical prostatectomy provide better outcomes? Our guest Dr. Tewari Ash, director of robotic prostatectomy and prostate cancer-urologic oncology outcomes at Brady Urology Institute and associate professor of associate professor of public health and outcomes in the Department of Public Health and Outcomes at The Weill Medical College of Cornell University talks with host Dr. Bruce Bloom about the history, current practice and future of robotic surgery. The hope is that one day the real time information gathered by the computer during the surgery will provide the surgeon with feedback that can enable them to do an even better job at removing the cancer.
Guest: Ash Tewari, MD
Host: Bruce Bloom, DDS, JD
Would experienced video gamers have a leg up in operating the DaVinci robot used in robotic surgery for prostate cancer? Dr. Ash Tewari, associate professor of urology, and director of Robotic Prostatectomy & Prostate Cancer-Urologic Oncology Outcomes at Brady Urology Institute, and associate professor of public health and outcomes at the Weill Medical College of Cornell University, answers this question posed by your host, Dr. Bruce Bloom. Listen in as Dr. Tewari describes the arena of this valuable surgical asset and why he labels the use of the Davinci robot - a technology originally designed for military and astronaut use - as a "marriage made in heaven" for prostatectomy.
Guest: Ash Tewari, MD
Host: Bruce Bloom, DDS, JD
Are your patients potential candidates for robotic prostatectomy? How precisely does robotic surgery treat prostate cancer while maintaining urinary and sexual function? Host Dr. Bruce Bloom addresses these questions with Dr. Ash Tewari, associate professor of urology, and director of Robotic Prostatectomy & Prostate Cancer-Urologic Oncology Outcomes at Brady Urology Institute at Weill Cornell Medical College. Dr. Tewari discusses candidate selection, the benefits of the robotic technique, and the most important factor for a successful surgery. What is it? Tune in to find out!
Guest: Charles Enke, MD
Host: Gary Kohn, MD
What's around the bend for radiation targeting systems? Dr. Charles Enke, professor and chair of radiation oncology at the University of Nebraska College of Medicine, speaks with host Dr. Gary Kohn about the potential of electromagnetic targeting and tracking as used in the GPS-like Calypso-guided technology. Detecting prostate motion in real-time, eliminating inter-observer variation, and providing the benefit of more precise radiation targeting are, as Dr. Enke mentions, just a few of the benefits with this new technology.
Guest: Charles Enke, MD
Host: Gary Kohn, MD
Keeping closer tabs on the intrafractional movement of the prostate during radiation therapy will continue to play an increasingly significant role in improving our overall success when treating prostate cancer. So says Dr. Charles Enke, professor and chair of radiation oncology at the University of Nebraska College of Medicine. He details the latest in prostate imaging with host Dr. Gary Kohn. How are we enhancing our command of real-time monitoring modalities?
Host: Leslie P. Lundt, MD
Guest: Lori Brotto, PhD
How do the age of first sexual intercourse and the emotional aspects of that experience contribute to later adult sexual functioning? Dr. Lori Brotto joins host Dr. Leslie Lundt to discuss her research in this area.
Guest: Craig Nichols, MD
Host: Mark Nolan Hill, MD
Testicular cancer has received significant media attention in recent years, thanks in part to the very public cancer battle of cyclist Lance Armstrong during the late 1990s. The treatment aspect of Armstrong’s spirited and ultimately successful drive to beat cancer was led by Dr. Craig Nichols who, at the time, was a professor of medicine in the division of hematology/oncology at the Indiana University School of Medicine.
Armstrong, now a seven-time Tour de France champion, has used his immense success as a springboard for the Lance Armstrong Foundation (LAF). We’ll learn more about the work of the LAF from Dr. Nichols. He serves as secretary and a member of the board of directors for the LAF, in addition to his duties as medical director of lymphoma and testicular cancer research at Providence Portland Medical Center in Portland, Oregon.
Dr. Nichols also shares his perspective on his patient’s success—both as a champion of cycling’s most prestigious event and a champion for the many millions of people battling cancer. Dr. Mark Nolan Hill hosts.
Host: Mark Nolan Hill, MD
Guest: Craig Nichols, MD
When patients think of testicular cancer, they immediately think of two ramifications: the impact on their fertility and on their sexuality. Are these concerns well-founded? How should we counsel our patients on these issues? Dr. Craig Nichols, medical director of lymphoma and testicular cancer research at Providence Portland Medical Center in Portland, Oregon, and an internationally respected expert on testicular cancer, explores these issues with host Dr. Mark Nolan Hill. How will the concerns of our patients change as we continue to improve our understanding and our treatment of testicular cancer?
Host: Mark Nolan Hill, MD
Guest: Craig Nichols, MD
Diagnosed in thousands of American men each year, testicular cancer has proven highly sensitive to current treatment regimens. Host Dr. Mark Nolan Hill evaluates the most common therapies for testicular cancer with Dr. Craig Nichols, medical director of lymphoma and testicular cancer research at Providence Portland Medical Center in Portland, Ore., and an internationally respected expert on testicular cancer. Are there significant side effects to the present therapies? Further, keeping in mind the possibility of a recurrent disease, and the accordant need for proper follow-up measures, Dr. Nichols evaluates strategies for coordinating care between medical oncologists and primary care physicians.
Host: Mark Nolan Hill, MD
Guest: Craig Nichols, MD
If detected in its early stages, we have great success in curing testicular cancer. What are our most effective screening measures? How should we instruct our patients to be vigilant with their own self-exams, or is this the best approach? Dr. Craig Nichols, medical director of lymphoma and testicular cancer research at Providence Portland Medical Center in Portland, Ore., and an internationally respected expert on testicular cancer, joins host Dr. Mark Nolan Hill to review our most effective defenses against this disease.
Guest: Walter Stadler, MD
Host: Bruce Bloom, DDS, JD
Targeted and Individualized Therapies for Cancer. Where are we? What's on the horizon? Associate Dean of Clinical Research, Professor of Medicine and Director of the Genitourinary program at the University of Chicago Pritzker School of Medicine, Dr. Walter Stadler, cites the majority of patients struggling with the side effects - while grasping for the benefits - of cancer therapy as a necessity for individualized therapy. Dr. Stadler and Dr. Bloom discuss individualized treatment as a reality via biomarker identification, and management of cancer heterogeneity of various cancers within the same patient.
Guest: Walter Stadler, MD
Host: Bruce Bloom, DDS, JD
Host Dr. Bruce Bloom welcomes Dr. Walter Stadler, professor of medicine and director of the genitourinary program at the University of Chicago Pritzker School of Medicine. We are still working toward a highly effective treatment for hormone refractory prostate cancer. Could a paradoxical treatment with high-dose testosterone hold the key to a cure? Dr. Stadler details current clinical research on this somewhat controversial topic.
Guest: Andrew Vickers, PhD
Host: Bill Rutenberg, MD
Can you predict a man’s risk of prostate cancer 25 years in the future? The data from this study indicates that PSA levels before age 50 is an indicator of future prostate cancer. Find out more about the prospective study conducted by a team of researchers from Memorial Sloane Kettering. Epidemiologist Andrew Vickers talks with host Dr. Bill Rutenberg about what the GP can take from this study What does a slightly elevated, but not high PSA indicate about the chance of prostate cancer in the future?
Host: Bill Rutenberg, MD
Guest: Andrew Vickers, PhD
We all know that practice makes perfect, but how much practice is necessary to be considered beyond the learning curve? In this segment, Dr. Andrew Vickers shares his research in which his team evaluated the surgical outcomes for radical prostectomies based on chemical recurrence. What do the outcomes of this study indicate about the training and experience level of surgeons? Join us to find out.
Guest: Anthony Bella, MD
Host: Leslie P. Lundt, MD
Vascular causes of ED may be the most common type of ED, but neurogenic ED is often the most difficult to treat. What should the clinician know about diagnosing and treating erectile dysfunction of neurogenic origin? Urologist Dr. Anthony Bella discusses his research with host Dr. Leslie Lundt.
Guest: Anthony Bella, MD
Host: Leslie P. Lundt, MD
Peyronie’s Disease is more common than most physicians realize, affecting 1 in 20 men. Does it always require surgery? Urologist Dr. Anthony Bella discuss treatment options with host Dr. Leslie Lundt.
Guest: Anthony Bella, MD
Host: Leslie P. Lundt, MD
The management of Peyronie's disease (PyD) presents several challenges to the clinician. Despite progress in the understanding of PyD on several fronts, it remains a physically and psychologically devastating condition for the affected patient and his partner. Anthony Bella MD, an international expert on PyD, joins host Dr. Leslie Lundt to discuss screening for this condition which affects 5% of adult males.
Guest: Robert Thompson, MD
Host: Gary Kohn, MD
Small Renal tumors: Are patients being properly counseled? With your host, Dr. Gary Kohn, is Robert "Houston" Thompson, Urologic Oncology Fellow, at Memorial Sloan Kettering Cancer Center in New York. Join the discussion as Dr. Thompson covers the management of small renal tumors, highlighting survival rates of patients treated with partial vs. radical nephrectomies.
Host: Gary Kohn, MD
Guest: Robert Thompson, MD
Small renal tumors and surgical judgement. Amongst patients with small renal tumors, what is the benefit of a partial nephrectomy vs. a total, or radical nephrectomy? Dr. Robert Thompson, a urologic oncology fellow at Memorial Sloan Kettering Cancer Center, discusses research published in the Journal of Urology with your host, Dr. Gary Kohn.
Guest: Paul Shin, MD
Host: Larry Kaskel, MD
What is known about the cause of Peyronie's Disease, and what are the latest treatments? Join host Dr. Larry Kaskel to discuss Peyronie's Disease with our guest, Dr. Paul Shin.
Guest: Paul Shin, MD
Host: Larry Kaskel, MD
Our guest, Dr. Paul Shin prefers to use the in-line vasectomy method on his patients. What is different about this technique and why is it better for the patients? Join host, Dr. Larry Kaskel to learn about in-line vasectomy and also about vasectomy reversal.
Guest: Paul Shin, MD
Host: Larry Kaskel, MD
Does daily dosing provide patients with ED a better option? Join host Dr. Larry Kaskel speaking with urologist Dr. Paul Shin about the various ED medications on the market and the differences between them.
Guest: Ken Brigham, MD
Host: Danny Petrasek, MD, PhD
The Emory/Georgia Tech Predictive Health Institute is building a new model of healthcare based on advances in science, technology and translational research combined with health economics, public policy, business and ethics. In this segment, host, Dr. Danny Petrasek speaks with the Institute's Director, Dr. Ken Brigham, about why it was formed and what they hope to accomplish.
Guest: Sharon Maynard, MD
Host: Bruce Bloom, DDS, JD
Sharon E. Maynard, M.D. Assistant Professor, Division of Renal Disease and Hypertension George Washington University in Washington, DC. Dr. Maynard is one of the world’s leaders in pre-eclampsia research and clinical care and joins us to talk about what life is like for a physician researcher.
Guest: Sharon Maynard, MD
Host: Bruce Bloom, DDS, JD
Sharon E. Maynard, M.D. Assistant Professor, Division of Renal Disease and Hypertension George Washington University in Washington, DC. Dr. Maynard is one of the world’s leaders in pre-eclampsia research and clinical care and joins us to talk about her research into what causes or could treat pre-eclampsia.
Guest: Sharon Maynard, MD
Host: Bruce Bloom, DDS, JD
Sharon E. Maynard, M.D. Assistant Professor, Division of Renal Disease and Hypertension George Washington University in Washington, DC. Dr. Maynard is one of the world’s leaders in pre-eclampsia research and clinical care and joins us to talk about her research into what causes or could treat pre-eclampsia.
Guest: Sharon Maynard, MD
Host: Bruce Bloom, DDS, JD
Dr. Maynard is one of the world’s leaders in pre-eclampsia research and clinical care and and joins us to talk about the signs, symptoms and treatments of pre-eclampsia
Guest: Brian Moran, MD
Host: Michael Greenberg, MD
Dr. Michael Greenberg speaks with Dr. Brian Moran, Medical Director of the Chicago Prostate Cancer Center, about new biopsy and diagnostic techniques for men with prostate cancer.
Guest: Brian Moran, MD
Host: Michael Greenberg, MD
Dr. Michael Greenberg speaks with Dr. Brian Moran, Medical Director of the Chicago Prostate Cancer Treatment Center, about the various treatments available for treating prostate cancer with an emphasis on brachytherapy.
Guest: Brian Moran, MD
Host: Michael Greenberg, MD
Dr. Michael Greenberg speaks with Dr. Brian Moran, medical director of the Chicago Prostate Cancer Center, about brachytherapy and Dr. Moran's personal journey in creating his nationally recognized prostate cancer treatment facility.
Guest: Richard Valicenti, MD
Host: Larry Kaskel, MD
What are the reasons a patient should have surgery vs. radiation therapy when trying to cure prostate cancer? When are both treatments recommended? Join oncology radiation specialist Dr. Rick Valicenti speak with host Dr. Larry Kaskel about the most promising treatments for prostate cancer patients.
Guest: Richard Valicenti, MD
Host: Larry Kaskel, MD
Join Host Dr. Larry Kaskel with Dr. Richard Valicenti, nationally known for radiotherapeutic managment of prostate cancer, talking about a new approach to Brachytherapy and 3D Conformal Radiation Therapy.
Guest: John Hollingsworth, MD
Host: Lee Freedman, MD
Dr. Hollingsworth discusses the use of alpha blockers and calcium channel blockers in helping with the passage of kidney stones.
Guest: John Hollingsworth, MD
Host: Lee Freedman, MD
Dr. Hollingsworth discusses traditional methods for assisting patients with the passage of kidney stones and why other therapies are needed.
Guest: Peter Muench, MD
Host: Mark Nolan Hill, MD
In this segment, Dr. Peter Muench re-explains the Green Light Laser Treatment for BPH and specifically addresses his experience with larger than average prostates.
Guest: Peter Muench, MD
Host: Mark Nolan Hill, MD
What are the benefits of Green Light Laser Vaporization for treating enlarged prostate? How long does it last? Is it any better than traditional treatments? In this segment we hear from Dr. Peter Muench who has performed more that 150 Green Light Laser Vaporization surgeries.
Guest: Peter Muench, MD
Host: Mark Nolan Hill, MD
In this segment, Dr. Muench discusses the possible treatment options for Benign Prostatic Hypertrophy and introduces a new therapy he uses called Green Light Laser.
Guest: Peter Muench, MD
Host: Mark Nolan Hill, MD
In this segment, Dr. Peter Muench explains the pathology of Benign Prostatic Hypertrophy and describes the evaluation process of an enlarged prostate.
Host: Larry Kaskel, MD
Guest: Elizabeth Tieman, MD
Work-life balance: how many of us can say we have it, let alone come close to having it? Board-certified radiologist Dr. Betsy Tieman is one healthcare professional who can say she achieved work-life balance by leaving private practice where she was working 14 hours a day to take advantage of locum tenens work, which also enabled her to train and compete in triathlons.
Guest: Jeanette Potts, MD
Host: Lee Freedman, MD
Dr. Potts describes treatment approaches to this common yet perplexing disorder which is also known as chronic pelvic pain syndrome. Dr. Potts stresses "thinking beyond the prostate" for this syndrome.
Guest: Jeanette Potts, MD
Host: Lee Freedman, MD
Dr. Potts describes the approach to and diagnosis of this common yet perplexing syndrome also known as chronic pelvic pain syndrome.
Guest: Jeanette Potts, MD
Host: Lee Freedman, MD
Dr. Potts describes the diagnosis and treatment of men with both acute and chronic bacterial prostatitis.
Guest: Jeanette Potts, MD
Host: Lee Freedman, MD
Dr. Potts describes the NIH classification scheme for prostatitis and the approach to the patient with LUTS and pelvic pain.
Guest: Myron Genel, MD
Host: Bill Rutenberg, MD
In this segment Dr. Genel explores the identification of gender and sexual disorders including hermaphrodism, androgen insensitivity disorder and sexual disphoria disorder.
Guest: Robert H. Getzenberg, PhD
Host: Paul Raeburn
A new test for prostate cancer promises to be far more accurate than the PSA in detecting prostate cancer. Sponsored by Amgen